Research programme: antisense CD40 inhibitors - Isis Pharmaceuticals/novosom AG
Latest Information Update: 23 Aug 2013
Price :
$50 *
At a glance
- Originator Isis Pharmaceuticals
- Developer novosom AG
- Class Antisense oligonucleotides
- Mechanism of Action CD40 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Inflammation